No indication for CALR mutation analysis in Irish patients presenting with deep vein thrombosis or pulmonary embolism

  • Stephen E. LangabeerEmail author
Letter to the Editor


Compliance with ethical standards

This study was performed in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments. Informed consent was obtained from participants at the referring centres.

Conflict of interest

The author declares that he has no conflicts of interest.


  1. 1.
    Martin K (2017) Risk factors for and management of MPN-associated bleeding and thrombosis. Curr Hematol Malig Rep 12:389–396CrossRefGoogle Scholar
  2. 2.
    Bertozzi I, Peroni E, Coltro G, Bogoni G, Cosi E, Santarossa C, Fabris F, Randi ML (2016) Thrombotic risk correlates with mutational status in true essential thrombocythemia. Eur J Clin Investig 46:683–689CrossRefGoogle Scholar
  3. 3.
    Zerjavic K, Zagradisnik B, Stangler Herodez S, Lokar L, Glaser Krasevac M, Kokalj Vokac N (2010) Is the JAK2 V617F mutation a hallmark for different forms of thrombosis? Acta Haematol 124:49–56CrossRefGoogle Scholar
  4. 4.
    Ianotto JC, Chauveau A, Luque Paz D, Delluc A, Tromeur C, Couturier MA, Gouillou M, Berthou C, Mottier D, Ugo V (2016) Absence of CALR mutation among a cohort of 394 unselected patients with a first episode of unprovoked venous thromboembolism. Thromb Haemost 115:225–226CrossRefGoogle Scholar
  5. 5.
    Ianotto JC, Chauveau A, Mottier D, Ugo V, Berthou C, Lippert E, Delluc A (2017) JAK2 V617F and calreticulin mutations in recurrent venous thromboembolism: results from the EDITH prospective cohort. Ann Hematol 96:383–386CrossRefGoogle Scholar

Copyright information

© Royal Academy of Medicine in Ireland 2019

Authors and Affiliations

  1. 1.Cancer Molecular Diagnostics, Central Pathology LaboratorySt. James’s HospitalDublinIreland

Personalised recommendations